演題抄録

International Symposium

開催概要
開催回
第53回・2015年・京都
 

Tumoral Heterogenity in Ovarian Cancer: Opportunities for Novel Treatment

演題番号 : IS2-3

[筆頭演者]
MacKay Helen:1 

1:Medical Oncology and Hematology, Medicine, University of Toronto, Canada

 

Epithelial ovarian cancer (EOC) is the second most common gynaecological malignancy and it is the leading cause of gynecologic cancer death in women. Most patients with EOC are diagnosed at the advanced stage. The primary treatment is cytoreductive surgery, followed by platinum-based chemotherapy; however, long-term survival remains poor, due to recurrent disease and emerging drug resistance. Novel treatment strategies are required to improve outcomes of women with EOC. Recent advances in molecular profiling have shown that cancers arising from the ovary are phenotypically and genetically heterogeneous. These data support the idea that different targeted agents may be effective within different ovarian histologies. Several of these targeted agents have entered clinical trials. Targeting angiogeneisis and and poly ADP ribose (PARP) inhibitors in select patients have entered the clinic. Ongoing trials are acquiring data on the biological and clinical consequence of target inhibition, immunotherpay and other promising therapeutoic stratefies which will hopefully translate into meaningful improvements in out come for women with EOC in the future

前へ戻る